Table 3. Relationship between CA125, CK7, CK20, and ER expressions and clinicopathological features.
| Variable | n | CA125 | Positive rate (%) | P value | CK7 | Positive rate (%) | P value | CK20 | Positive rate (%) | P value | ER | Positive rate (%) | P value | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| − | + | − | + | − | + | − | + | ||||||||||
| Age (years) | <0.05 | <0.05 | <0.05 | <0.05 | |||||||||||||
| <50 | 64 | 2 | 16 | 25 | 1 | 14 | 21.9 | 9 | 2 | 3.1 | 20 | 24 | 37.5 | ||||
| ≥50 | 189 | 4 | 29 | 15.3 | 1 | 33 | 17.9 | 23 | 2 | 1.1 | 37 | 54 | 28.6 | ||||
| Pathological type | 0.3192 | 0.0259 | |||||||||||||||
| Serous | 86 | 0 | 11 | 12.8 | 1 | 8 | 9.3 | 3 | 0 | 0 | 0.5460 | 19 | 33 | 38.4 | 0.1430 | ||
| Mucinous | 16 | 1 | 2 | 12.5 | 1 | 2 | 12.5 | 2 | 1 | 6.3 | 7 | 2 | 12.5 | ||||
| Endometrioid | 15 | 0 | 3 | 20 | 0 | 3 | 20 | 2 | 0 | 0 | 3 | 4 | 26.7 | ||||
| Others | 136 | 5 | 28 | 20.6 | 0 | 34 | 25 | 25 | 3 | 2.2 | 28 | 33 | 24.3 | ||||
| Tissue differentiation | 0.0773 | <0.05 | <0.05 | 0.4771 | |||||||||||||
| High | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 50 | ||||
| Moderate | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 40 | ||||
| Low | 111 | 4 | 23 | 20.7 | 0 | 28 | 25.2 | 17 | 1 | 0.9 | 26 | 36 | 32.4 | ||||
| FIGO stage | 0 | <0.05 | 1.0000 | 1.0000 | <0.05 | ||||||||||||
| I‒II | 55 | 2 | 5 | 9.1 | 0 | 10 | 18.2 | 6 | 1 | 1.8 | 17 | 10 | 18.2 | ||||
| III‒IV | 198 | 4 | 39 | 19.7 | 2 | 37 | 18.7 | 26 | 3 | 1.5 | 40 | 63 | 31.8 | ||||
| Residual lesions | 0.6615 | <0.0001 | 0.4593 | 0.4082 | |||||||||||||
| 0 | 53 | 0 | 5 | 9.4 | 0 | 7 | 13.2 | 3 | 1 | 1.9 | 13 | 17 | 32.1 | ||||
| 1 | 174 | 5 | 35 | 20.1 | 1 | 35 | 20.1 | 25 | 2 | 1.1 | 40 | 54 | 31.0 | ||||
| 2 | 26 | 1 | 5 | 19.2 | 5 | 1 | 3.8 | 4 | 1 | 3.8 | 7 | 4 | 15.4 | ||||
−, negative; +, positive. ER, estrogen receptor; FIGO, federation of international gynecology and obstetrics.